OncLive® On Air

Dr Patil emphasized the significance of the phase 3 CROWN trial (NCT03052608), which compared lorlatinib (Lorbrena) with crizotinib (Xalkori) in patients with ALK-positive metastatic NSCLC. With a hazard ratio of 0.19 (95% CI, 0.13-0.27) for progression-free survival, the trial demonstrated lorlatinib’s superior intracranial control and long-term efficacy compared with crizotinib, especially in pa...

In today’s episode, supported by Sobi, we had the pleasure of speaking with Aaron T. Gerds, MD, MS, and James K. McCloskey, MD, about myelofibrosis treatment advances. Dr Gerds is an assistant professor in the Department of Medicine in the School of Medicine, as well as a member of the Developmental Therapeutics Program at the Case Comprehensive Cancer Center in Cleveland, Ohio. He is also a physi...

In today’s episode, supported by Servier Pharmaceuticals, we had the pleasure of speaking with Jennie W. Taylor, MD, MPH, about the FDA approval of vorasidenib (Voranigo) for patients with IDH -positive grade 2 astrocytoma or oligodendroglioma. Dr Taylor is an associate professor of clinical neurology at the University of California, San Francisco (UCSF), as well as the community engagement liaiso...

In our exclusive interview, Dr Dietrich discussed key efficacy findings from the 18-month follow-up of the phase 2 VISION trial (NCT02864992), which evaluated the efficacy of tepotinib (Tepmetko) in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations. Additionally, Dr Dietrich emphasized important safety considerations with tepotinib, particularly the management of on...

In today’s episode, supported by AstraZeneca, we had the pleasure of speaking with Sandip P. Patel, MD, and Brendon M. Stiles, MD, about the FDA approval of perioperative durvalumab (Imfinzi) for patients with resectable non–small cell lung cancer (NSCLC). Dr Patel is a professor of medicine in the Department of Medicine at the University of California, San Diego. Dr Stiles is a professor of cardi...

In part 2 of this 3-part Oncology Unplugged series, Chandler Park, MD, a genitourinary medical oncologist at Norton Cancer Institute in Louisville, Kentucky, and Tejas Patil, MD, an assistant professor of medical oncology at the University of Colorado School of Medicine in Aurora, discussed the evolving small cell lung cancer (SCLC) treatment paradigm. They examined critical data from recent studi...

Two Onc Docs , hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematolog...

In today’s episode, we had the pleasure of speaking with Rory Shallis, MD, an assistant professor of medicine and hematology at Yale School of Medicine, part of Yale New Haven Health in Connecticut. Shallis sat down with us to share some of the research that has been generated in myelodysplastic syndrome (MDS) over the past year or so, touching on the evolution of clinical trial end points and whe...

Dr Warner discusses the FDA approval of afami-cel for patients with advanced synovial sarcoma and key findings from the pivotal SPEARHEAD-1 trial.

Welcome to OncLive On Air ®! I’m your host today, Ashling Wahner.  OncLive On Air is a podcast from OncLive ®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.  In today’s...

In Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a genitourinary medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, sits down with Tejas Patil, MD, an assistant professor of medicine-medical oncology at the University of Colorado School of Medicine - Anschutz Medical Campus in Aurora. In this episode, Drs Park and Patil discuss key updates...

Welcome to OncLive On Air ®! I’m your host today, Ashling Wahner.  OncLive On Air  is a podcast from OncLive ®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.  In today’...

In today’s episode, we invited experts from across oncology specialties to discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress. Emre Yekedüz, MD, an associate professor of medical oncology at Ankara University in Turkey and a research fellow at Dana-Farber Cancer Institute in Boston, Massachusetts, shared insights on his latest work in gastroin...

Two Onc Docs , hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematolog...

In today’s episode, we had the pleasure of speaking with Narjust Florez, MD, about patient-focused lung cancer biomarker testing discussions.

Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.

Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.

Dr Chiang discusses the use of lurbinectedin in small cell lung cancer and tips for managing toxicities associated with this agent.

Dr Tewari discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

Dr Jhaveri discusses the INAVO120 trial of inavolisib plus palbociclib and fulvestrant in PIK3CA-mutant, HR-positive metastatic breast cancer.

Drs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.

Dr Garcia-Manero discusses findings from research in myelodysplastic syndromes that were presented at the 2024 EHA Congress.

Dr Westin discusses the FDA approval of durvalumab plus chemotherapy for patients with dMMR advanced or recurrent endometrial cancer.

Drs Armstrong and Tawagi discuss the NADINA trial of neoadjuvant nivolumab/ipilimumab vs adjuvant nivolumab in resectable, macroscopic, stage III melanoma.

Dr Rotow discusses data that demonstrated the central nervous system activity of datopotamab deruxtecan and osimertinib in patients with NSCLC.